Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT JR pediatric generalized myasthenia gravis trial of intravenous efgartigimod
NL-OMON60298Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Jun 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoints: Efgartigimod concentrations for model-driven PK analysis and Pharmacodynamic markers for PK/PD modeling. Started Jun 2022; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON60298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60298.